Darwin AG Launches Multi-Cancer Check for Early Cancer Detection

Munich-based Darwin AG has announced the launch of its Multi-Cancer Check, a blood test designed to detect 13 types of cancer early. This test, a result of collaboration with Wholomics GmbH, will be marketed primarily through NovoMedic GmbH, a Darwin AG subsidiary. The test employs liquid biopsy technology and multi-omics analysis, offering a non-invasive method to identify cancer at early stages.

The Multi-Cancer Check can detect various tumors simultaneously, unlike traditional tests. It covers cancers like colon, lung, and bladder. A study involving 862 samples, 440 of which were cancer cases, showed a sensitivity of 80.7% and specificity of 99.1%, with only three false positives recorded.

CEO Dr. Daniel Wallerstorfer highlighted the test’s potential in improving cancer survival rates through early detection. It uses AI to evaluate molecular signals, suggesting positive results be confirmed via imaging. With the liquid biopsy market poised for growth, this test contributes to non-invasive cancer diagnostics.